429 related articles for article (PubMed ID: 20615753)
1. Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?
Kloosterhof NK; Bralten LB; Dubbink HJ; French PJ; van den Bent MJ
Lancet Oncol; 2011 Jan; 12(1):83-91. PubMed ID: 20615753
[TBL] [Abstract][Full Text] [Related]
2. [IDH1/2 mutations in gliomas].
Nobusawa S; Yokoo H
Brain Nerve; 2011 Dec; 63(12):1378-86. PubMed ID: 22147457
[TBL] [Abstract][Full Text] [Related]
3. IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma.
Zhang C; Moore LM; Li X; Yung WK; Zhang W
Neuro Oncol; 2013 Sep; 15(9):1114-26. PubMed ID: 23877318
[TBL] [Abstract][Full Text] [Related]
4. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
Hartmann C; Meyer J; Balss J; Capper D; Mueller W; Christians A; Felsberg J; Wolter M; Mawrin C; Wick W; Weller M; Herold-Mende C; Unterberg A; Jeuken JW; Wesseling P; Reifenberger G; von Deimling A
Acta Neuropathol; 2009 Oct; 118(4):469-74. PubMed ID: 19554337
[TBL] [Abstract][Full Text] [Related]
5. Clinico-neuropathological features of isocitrate dehydrogenase 2 gene mutations in lower-grade gliomas.
Wang LM; Li Z; Piao YS; Cai YN; Zhang LY; Ge HJ; Xu WW; Lu DH
Chin Med J (Engl); 2019 Dec; 132(24):2920-2926. PubMed ID: 31833906
[TBL] [Abstract][Full Text] [Related]
6. All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2.
Labussière M; Idbaih A; Wang XW; Marie Y; Boisselier B; Falet C; Paris S; Laffaire J; Carpentier C; Crinière E; Ducray F; El Hallani S; Mokhtari K; Hoang-Xuan K; Delattre JY; Sanson M
Neurology; 2010 Jun; 74(23):1886-90. PubMed ID: 20427748
[TBL] [Abstract][Full Text] [Related]
7. The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas.
Wang HY; Tang K; Liang TY; Zhang WZ; Li JY; Wang W; Hu HM; Li MY; Wang HQ; He XZ; Zhu ZY; Liu YW; Zhang SZ
J Exp Clin Cancer Res; 2016 May; 35():86. PubMed ID: 27245697
[TBL] [Abstract][Full Text] [Related]
8. Molecular pathogenesis of IDH mutations in gliomas.
Ichimura K
Brain Tumor Pathol; 2012 Jul; 29(3):131-9. PubMed ID: 22399191
[TBL] [Abstract][Full Text] [Related]
9. 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.
Jin G; Reitman ZJ; Spasojevic I; Batinic-Haberle I; Yang J; Schmidt-Kittler O; Bigner DD; Yan H
PLoS One; 2011 Feb; 6(2):e16812. PubMed ID: 21326614
[TBL] [Abstract][Full Text] [Related]
10. IDH1 and IDH2 mutations in gliomas.
Yan H; Parsons DW; Jin G; McLendon R; Rasheed BA; Yuan W; Kos I; Batinic-Haberle I; Jones S; Riggins GJ; Friedman H; Friedman A; Reardon D; Herndon J; Kinzler KW; Velculescu VE; Vogelstein B; Bigner DD
N Engl J Med; 2009 Feb; 360(8):765-73. PubMed ID: 19228619
[TBL] [Abstract][Full Text] [Related]
11. Metabolism of glioma and IDH1/IDH2 mutations.
Rossetto M; Ciccarino P; Boisselier B; Labussiere M; Sanson M
Rev Neurol (Paris); 2011 Oct; 167(10):699-703. PubMed ID: 21885076
[TBL] [Abstract][Full Text] [Related]
12. Association Between IDH1 and IDH2 Mutations and Preoperative Seizures in Patients with Low-Grade Versus High-Grade Glioma: A Systematic Review and Meta-Analysis.
Phan K; Ng W; Lu VM; McDonald KL; Fairhall J; Reddy R; Wilson P
World Neurosurg; 2018 Mar; 111():e539-e545. PubMed ID: 29288860
[TBL] [Abstract][Full Text] [Related]
13. Isocitrate dehydrogenase mutations: a challenge to traditional views on the genesis and malignant progression of gliomas.
Weller M; Wick W; von Deimling A
Glia; 2011 Aug; 59(8):1200-4. PubMed ID: 21294161
[TBL] [Abstract][Full Text] [Related]
14. Isocitrate Dehydrogenase
Murugan AK; Alzahrani AS
Br J Biomed Sci; 2022; 79():10208. PubMed ID: 35996504
[No Abstract] [Full Text] [Related]
15. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
[TBL] [Abstract][Full Text] [Related]
16. Biological Significance of Mutant Isocitrate Dehydrogenase 1 and 2 in Gliomagenesis.
Ohba S; Hirose Y
Neurol Med Chir (Tokyo); 2016; 56(4):170-9. PubMed ID: 26960449
[TBL] [Abstract][Full Text] [Related]
17. Establishment of a multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations.
Kato Kaneko M; Ogasawara S; Kato Y
Tohoku J Exp Med; 2013 Jun; 230(2):103-9. PubMed ID: 23782684
[TBL] [Abstract][Full Text] [Related]
18. Pyrosequencing of IDH1 and IDH2 mutations in brain tumors and non-neoplastic conditions.
Cykowski MD; Allen RA; Fung KM; Harmon MA; Dunn ST
Diagn Mol Pathol; 2012 Dec; 21(4):214-20. PubMed ID: 23111198
[TBL] [Abstract][Full Text] [Related]
19. Molecular classification of low-grade diffuse gliomas.
Kim YH; Nobusawa S; Mittelbronn M; Paulus W; Brokinkel B; Keyvani K; Sure U; Wrede K; Nakazato Y; Tanaka Y; Vital A; Mariani L; Stawski R; Watanabe T; De Girolami U; Kleihues P; Ohgaki H
Am J Pathol; 2010 Dec; 177(6):2708-14. PubMed ID: 21075857
[TBL] [Abstract][Full Text] [Related]
20. IDH mutations in glioma and acute myeloid leukemia.
Dang L; Jin S; Su SM
Trends Mol Med; 2010 Sep; 16(9):387-97. PubMed ID: 20692206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
